Apogee Therapeutics, Inc. · NASDAQ:APGE

Apogee Therapeutics — Corporate Update (November 2025)

15 slides from Apogee Therapeutics's corporate update, Nov 10, 2025

  1. Slide 1: APG333 Phase 1 Interim Results

    APG333 Phase 1 Interim Title text 2 Results November 10th, 2025

  2. Slide 2: Disclaimers and Forward-looking statements

    Disclaimers and Forward-looking statements This presentation contains certain "forward-looking statements" within the meaning of applicable securities laws. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements ab

  3. Slide 3: Monotherapies have hit an efficacy ceiling in asthma and COPD

    Monotherapies have hit an efficacy ceiling in asthma and COPD (Approval year in asthma) 100 Asthma labeled population 90 80 Reduction in asthma exacerbations 70 Monotherapy “efficacy ceiling” 60 50 TSLP IL-4R⍺ (Approved 2018) (Approved 2021) 40 IL-5 30 (Approved 2015) 20 IL-5 (Approved 2017) 10 0 0

  4. Slide 4: Targeting both IL-13 and TSLP could more broadly address the key drivers of obstructive airway disease

    Targeting both IL-13 and TSLP could more broadly address the key drivers of obstructive airway disease APG777 targets IL-13: addresses local airway responses (e.g., airway remodeling, mucus production) APG333 targets TSLP: blocks immune cell recruitment / activation (e.g., eosinophils) Potential to

  5. Slide 5: APG333 Phase 1 Interim Results

    APG333 Phase 1 Interim Results

  6. Slide 6: Interim APG333 Phase 1 data achieved or exceeded trial objectives

    APG 333 PHASE 1 Interim APG333 Phase 1 data achieved or exceeded trial objectives GOAL GOAL GOAL Confirm tolerable safety Establish optimized PK Demonstrate profile to enable future profile supporting every pharmacodynamic response combination trials 3-month dosing or better comparable to tezepeluma

  7. Slide 7: APG333 Phase 1 in healthy volunteers is fully enrolled with interim data from all cohorts

    APG 333 PHASE 1 APG333 Phase 1 in healthy volunteers is fully enrolled with interim data from all cohorts Trial design elements Single ascending dose Double-blind, placebo-controlled, 1000 mg (SQ) first-in-human trial Single ascending dose in healthy volunteers ×1 dose 500 mg (SQ) N = 32 ×1 dose 8 p

  8. Slide 8: Baseline characteristics were in line with expectations

    APG 333 PHASE 1 Baseline characteristics were in line with expectations Single dose Placebo APG333 Cohort 1 APG333 Cohort 2 APG333 Cohort 3 APG333 Cohort 4 125 mg 250 mg 500 mg 1000 mg N=8 N=6 N=6 N=6 N=6 Age (yrs), mean (SD) 40.5 (12.9) 31.5 (15.6) 37.8 (14.1) 31.5 (6.6) 28.0 (7.3) Female 62.5% 50.

  9. Slide 9: APG333 was well-tolerated and exhibited a safety profile consistent with the TSLP class

    APG 333 PHASE 1 APG333 was well-tolerated and exhibited a safety profile consistent with the TSLP class Single dose Overall trial APG333 APG333 APG333 APG333 Placebo Cohort 1 Cohort 2 Cohort 3 Cohort 4 Placebo APG333 125 mg 250 mg 500 mg 1000 mg N=8 N=6 N=6 N=6 N=6 N=8 N=24 ≥1 TEAE 3 (37.5) 4 (66.7)

  10. Slide 10: APG333 demonstrated an interim half-life of ~55 days

    APG 333 PHASE 1 APG333 demonstrated an interim half-life of ~55 days APG333 single-dose concentration-time profile1 Modeled exposures based on APG333 Phase 1 PK2 100 Median and 90% PI APG333 (lower dose) every 3 months 1000 125 mg (N=6) 500 mg (N=6) Concentration, μg/mL 250 mg (N=6) 1000 mg (N=6) 30

  11. Slide 11: Single dose of APG333 demonstrated durable biomarker suppression in HVs through 6-months

    APG 333 PHASE 1 Single dose of APG333 demonstrated durable biomarker suppression in HVs through 6-months; depth of suppression was comparable to TEZSPIRE Blood Eosinophil Counts IL-5 Placebo (N=8) APG333 125mg (N=6) Placebo (N=8) APG333 125mg (N=6) 40 20 Percent change from baseline (median) Percent

  12. Slide 12: APG273 (APG777+APG333)

    APG273 (APG777+APG333)

  13. Slide 13: APG273 combines validated mechanisms for potentially best-in-class efficacy and dosing

    APG 273 APG273 (APG777+APG333) combines validated mechanisms for potentially best-in-class efficacy and dosing in obstructive airway disease OVERLAPPING OPTIMIZED PK AND BROAD & ROBUST EPITOPE FORMULATION INHIBITION HUMAN IL-13 Preclinical data 77-day Airway Eosinophil human half-life APG777 remodel

  14. Slide 14: Clinical POC for combining IL-13 + TSLP inhibition exists with lunsekimig

    APG 273 Clinical POC for combining IL-13 + TSLP inhibition exists with lunsekimig FeNO data from lunsekimig asthma Ph1b demonstrates potential Lunsekimig has multiple readouts in next ~18 for combos to break through the monotherapy efficacy ceiling months, including Ph2b asthma data in 1H 2026 0 PAT

  15. Slide 15: Apogee

    Apogee /ˈapəjē/ noun The highest point in the development of something; a climax or culmination

Apogee Therapeutics — Corporate Update (November 2025) on 6ix